{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T03:02:57Z","timestamp":1790996577991,"version":"4.1.0"},"reference-count":60,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T00:00:00Z","timestamp":1744243200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background: Fatigue is a common and debilitating non-motor symptom (NMS) in Parkinson\u2019s disease (PD), significantly affecting patients\u2019 quality of life. MAO-B inhibitors are effective therapy for motor symptoms and fluctuations and may also play a role in fatigue management. Methods: We searched PubMed for English-language articles (January 1978\u2013August 2024) using keywords including \u201cselegiline\u201d, \u201crasagiline\u201d, \u201csafinamide\u201d, \u201cMAO-B\u201d, \u201cfatigue\u201d, and \u201cParkinson\u2019s disease\u201d. Clinical trials, observational, and preclinical studies were included. Results: While the role of MAO-B inhibitors in fatigue remains unclear, evidence suggests potential benefits. Selegiline has shown effectiveness in improving fatigue in animal models, supporting its potential utility in treating fatigue and motivational impairments in PD patients. Rasagiline has been associated with reduced fatigue progression in early PD, with some studies showing significant improvements compared to placebo. Safinamide, with its dual action as an MAO-B inhibitor and glutamate modulator, may further enhance fatigue management. Its ability to reduce glutamate release is particularly relevant, given the role of glutamate overactivity in PD-related fatigue. Studies indicate safinamide can significantly reduce fatigue levels. Conclusions: Fatigue in PD is a complex symptom with multiple contributing factors. While MAO-B inhibitors may support fatigue management, their precise role and optimal use require further investigation.<\/jats:p>","DOI":"10.3390\/jcm14082598","type":"journal-article","created":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T05:28:07Z","timestamp":1744262887000},"page":"2598","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["The Role of MAO-B Inhibitors in Fatigue in Parkinson\u2019s Disease: A Narrative Review"],"prefix":"10.3390","volume":"14","author":[{"given":"Silvia","family":"Galli","sequence":"first","affiliation":[{"name":"Department of Neuroscience, Mental Health and Sensory Organs (NESMOS), Sapienza University of Rome, Via di Grottarossa, 1035, 00189 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-6839-6119","authenticated-orcid":false,"given":"Pierre","family":"Pacilio","sequence":"additional","affiliation":[{"name":"Department of Neuroscience, Mental Health and Sensory Organs (NESMOS), Sapienza University of Rome, Via di Grottarossa, 1035, 00189 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7955-3369","authenticated-orcid":false,"given":"Edoardo","family":"Bianchini","sequence":"additional","affiliation":[{"name":"Department of Neuroscience, Mental Health and Sensory Organs (NESMOS), Sapienza University of Rome, Via di Grottarossa, 1035, 00189 Rome, Italy"},{"name":"AGEIS (Autonomy, Gerontology, E-Health, Imaging & Society Unit\u00e9 de Recherche), Universit\u00e9 Grenoble Alpes, 38000 Grenoble, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marika","family":"Alborghetti","sequence":"additional","affiliation":[{"name":"Department of Neuroscience, Mental Health and Sensory Organs (NESMOS), Sapienza University of Rome, Via di Grottarossa, 1035, 00189 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-0478-4523","authenticated-orcid":false,"given":"Lanfranco","family":"De Carolis","sequence":"additional","affiliation":[{"name":"Department of Neuroscience, Mental Health and Sensory Organs (NESMOS), Sapienza University of Rome, Via di Grottarossa, 1035, 00189 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Lombardo","sequence":"additional","affiliation":[{"name":"Department of Neuroscience, Mental Health and Sensory Organs (NESMOS), Sapienza University of Rome, Via di Grottarossa, 1035, 00189 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Garramone","sequence":"additional","affiliation":[{"name":"Department of Neuroscience, Mental Health and Sensory Organs (NESMOS), Sapienza University of Rome, Via di Grottarossa, 1035, 00189 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0501-8803","authenticated-orcid":false,"given":"Marco","family":"Salvetti","sequence":"additional","affiliation":[{"name":"Department of Neuroscience, Mental Health and Sensory Organs (NESMOS), Sapienza University of Rome, Via di Grottarossa, 1035, 00189 Rome, Italy"},{"name":"Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Neurologico Mediterraneo Neuromed, 86077 Pozzilli, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domiziana","family":"Rinaldi","sequence":"additional","affiliation":[{"name":"Department of Neuroscience, Mental Health and Sensory Organs (NESMOS), Sapienza University of Rome, Via di Grottarossa, 1035, 00189 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,4,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1016\/S0140-6736(21)00218-X","article-title":"Parkinson\u2019s disease","volume":"397","author":"Bloem","year":"2021","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/j.1468-1331.2008.02056.x","article-title":"Non-motor symptoms in Parkinson\u2019s disease","volume":"15","author":"Poewe","year":"2008","journal-title":"Eur. J. Neurol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.revmed.2020.06.019","article-title":"Les sympt\u00f4mes non-moteurs de la maladie de Parkinson de la physiopathologie au diagnostic pr\u00e9coce [Non-motor symptoms of Parkinson\u2019s disease from pathophysiology to early diagnosis]","volume":"42","author":"Aubignat","year":"2021","journal-title":"Rev. Med. Interne"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1002\/mds.21240","article-title":"Fatigue in Parkinson\u2019s disease: A review","volume":"22","author":"Friedman","year":"2007","journal-title":"Mov. Disord."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jns.2016.12.061","article-title":"Fatigue in Parkinson\u2019s disease","volume":"374","author":"Herlofson","year":"2017","journal-title":"J. Neurol. Sci."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1002\/mds.20459","article-title":"Pathophysiology of motor fluctuations in Parkinson\u2019s disease","volume":"20","author":"Widnell","year":"2005","journal-title":"Mov. Disord."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1002\/mds.27372","article-title":"International Parkinson and movement disorder society evidence-based medicine review: Update on treatments for the motor symptoms of Parkinson\u2019s disease","volume":"33","author":"Fox","year":"2018","journal-title":"Mov. Disord."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s00702-018-1952-7","article-title":"Inhibitors of MAO-B and COMT: Their effects on brain dopamine levels and uses in Parkinson\u2019s disease","volume":"126","author":"Finberg","year":"2019","journal-title":"J. Neural. Transm."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1212\/WNL.43.10.2016","article-title":"Fatigue in Parkinson\u2019s disease","volume":"43","author":"Friedman","year":"1993","journal-title":"Neurology"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1002\/mds.22989","article-title":"Fatigue rating scales critique and recommendations by the Movement Disorders Society task force on rating scales for Parkinson\u2019s disease","volume":"25","author":"Friedman","year":"2010","journal-title":"Mov. Disord."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/j.parkreldis.2013.07.010","article-title":"Importance of motor vs. non-motor symptoms for health-related quality of life in early Parkinson\u2019s disease","volume":"19","author":"Assmus","year":"2013","journal-title":"Parkinsonism. Relat. Disord."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"S119","DOI":"10.1016\/j.parkreldis.2015.09.004","article-title":"Non-motor symptoms in Parkinson\u2019s disease","volume":"22","author":"Pfeiffer","year":"2016","journal-title":"Parkinsonism. Relat. Disord."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1212\/WNL.0b013e31827f07be","article-title":"Fatigue and fatigability in neurologic illnesses: Proposal for a unified taxonomy","volume":"80","author":"Kluger","year":"2013","journal-title":"Neurology"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"195","DOI":"10.2165\/00002512-200926030-00002","article-title":"Physical and mental fatigue in Parkinson\u2019s disease: Epidemiology, pathophysiology and treatment","volume":"26","author":"Lou","year":"2009","journal-title":"Drugs Aging."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.clinph.2019.01.017","article-title":"Central fatigue and attentional processing in Parkinson\u2019s disease: An event-related potentials study","volume":"130","author":"Pauletti","year":"2019","journal-title":"Clin. Neurophysiol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1002\/mds.26650","article-title":"Functional connectivity underpinnings of fatigue in \u201cDrug-Na\u00efve\u201d patients with Parkinson\u2019s disease","volume":"31","author":"Tessitore","year":"2016","journal-title":"Mov. Disord."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1007\/s00702-020-02219-6","article-title":"Supplementary motor area functional connectivity in \u201cdrug-na\u00efve\u201d Parkinson\u2019s disease patients with fatigue","volume":"127","author":"Siciliano","year":"2020","journal-title":"J. Neural. Transm."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1212\/01.wnl.0000324862.29733.69","article-title":"Fatigue in levodopa-naive subjects with Parkinson disease","volume":"71","author":"Schifitto","year":"2008","journal-title":"Neurology"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"3434","DOI":"10.1093\/brain\/awq268","article-title":"Fatigue in Parkinson\u2019s disease is linked to striatal and limbic serotonergic dysfunction","volume":"133","author":"Pavese","year":"2010","journal-title":"Brain"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.bbi.2013.07.007","article-title":"Cerebrospinal fluid inflammatory markers in Parkinson\u2019s disease\u2014Association with depression, fatigue, and cognitive impairment","volume":"33","author":"Lindqvist","year":"2013","journal-title":"Brain Behav. Immun."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/S0140-6736(04)15794-2","article-title":"Fatigue in neurological disorders","volume":"363","author":"Chaudhuri","year":"2004","journal-title":"Lancet"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1002\/mds.23744","article-title":"Does cardiovascular autonomic dysfunction contribute to fatigue in Parkinson\u2019s disease?","volume":"26","author":"Nakamura","year":"2011","journal-title":"Mov. Disord."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"335","DOI":"10.5603\/PJNNS.a2023.0044","article-title":"Role of orexin in pathogenesis of neurodegenerative parkinsonisms","volume":"57","author":"Alster","year":"2023","journal-title":"Neurol. Neurochir. Pol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/S0022-510X(00)00411-1","article-title":"Fatigue and basal ganglia","volume":"179","author":"Chaudhuri","year":"2000","journal-title":"J. Neurol. Sci."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/bs.irn.2017.05.007","article-title":"Fatigue in Parkinson\u2019s Disease","volume":"133","author":"Kluger","year":"2017","journal-title":"Int Rev Neurobiol."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Diaconu, S., Monescu, V., Filip, R., Marian, L., Kakucs, C., Murasan, I., Chaudhuri, K.R., Jianu, D.C., Falup-Pecurariu, C., and Opritoiu, B. (2024). The Impact of Fatigue on Sleep and Other Non-Motor Symptoms in Parkinson\u2019s Disease. Brain Sci., 14.","DOI":"10.3390\/brainsci14040397"},{"key":"ref_27","first-page":"9614163","article-title":"Mental Fatigue in Parkinson\u2019s Disease: Systematic Review and Evaluation of Self-Reported Fatigue Scales","volume":"2024","author":"Chen","year":"2024","journal-title":"Park. Dis."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1002\/mds.10505","article-title":"Levodopa improves physical fatigue in Parkinson\u2019s disease: A double-blind, placebo-controlled, crossover study","volume":"18","author":"Lou","year":"2003","journal-title":"Mov. Disord."},{"key":"ref_29","first-page":"477","article-title":"Monoamine Oxidase-B Inhibitors for the Treatment of Parkinson\u2019s Disease: Past, Present, and Future","volume":"12","author":"Tan","year":"2022","journal-title":"J. Park. Dis."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S1474-4422(06)70373-8","article-title":"Non-motor symptoms of Parkinson\u2019s disease: Diagnosis and management","volume":"5","author":"Chaudhuri","year":"2006","journal-title":"Lancet Neurol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1007\/s00702-022-02465-w","article-title":"A critical appraisal of MAO-B inhibitors in the treatment of Parkinson\u2019s disease","volume":"129","author":"Jost","year":"2022","journal-title":"J. Neural. Transm."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"196","DOI":"10.4212\/cjhp.v71i3.2586","article-title":"Interaction between Monoamine Oxidase B Inhibitors and Selective Serotonin Reuptake Inhibitors","volume":"71","author":"Aboukarr","year":"2018","journal-title":"Can. J. Hosp. Pharm."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/s41531-022-00339-2","article-title":"Effects of MAO-B inhibitors on non-motor symptoms and quality of life in Parkinson\u2019s disease: A systematic review","volume":"8","author":"Tsuboi","year":"2022","journal-title":"NPJ Park. Dis."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"16","DOI":"10.4103\/1673-5374.375299","article-title":"Type-B monoamine oxidase inhibitors in neurological diseases: Clinical applications based on preclinical findings","volume":"19","author":"Alborghetti","year":"2024","journal-title":"Neural Regen. Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/B978-0-12-386467-3.00004-2","article-title":"The pharmacology of selegiline","volume":"100","author":"Magyar","year":"2011","journal-title":"Int. Rev. Neurobiol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.bbr.2017.12.039","article-title":"The monoamine-oxidase B inhibitor deprenyl increases selection of high-effort activity in rats tested on a progressive ratio\/chow feeding choice procedure: Implications for treating motivational dysfunctions","volume":"342","author":"Yohn","year":"2018","journal-title":"Behav. Brain Res."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/ene.12205","article-title":"Benefits of treatment with rasagiline for fatigue symptoms in patients with early Parkinson\u2019s disease","volume":"21","author":"Stocchi","year":"2014","journal-title":"Eur. J. Neurol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1001\/jamaneurol.2014.2472","article-title":"Combined rasagiline and antidepressant use in Parkinson disease in the ADAGIO study: Effects on nonmotor symptoms and tolerability","volume":"72","author":"Smith","year":"2015","journal-title":"JAMA Neurol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1002\/mds.26429","article-title":"Rasagiline for the symptomatic treatment of fatigue in Parkinson\u2019s disease","volume":"30","author":"Lim","year":"2015","journal-title":"Mov. Disord."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Solla, P., Ercoli, T., Masala, C., Orofino, G., Fadda, L., Corda, D.G., Zarbo, I.R., Meloni, M., Sechi, E., and Bagella, C.F. (2022). Rasagiline Withdrawal Syndrome in Parkinson\u2019s Disease. Brain Sci., 12.","DOI":"10.3390\/brainsci12020219"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Santos Garc\u00eda, D., Labandeira Guerra, C., Y\u00e1\u00f1ez Ba\u00f1a, R., Cimas Hernando, M.I., Cabo L\u00f3pez, I., Paz Gon\u00e1lez, J.M., Alonso Losada, M.G., Gonz\u00e1lez Palm\u00e1s, M.J., and Mart\u00ednez Mir\u00f3, C. (2021). Safinamide Improves Non-Motor Symptoms Burden in Parkinson\u2019s Disease: An Open-Label Prospective Study. Brain Sci., 11.","DOI":"10.3390\/brainsci11030316"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s10072-021-05324-w","article-title":"Effects of safinamide on non-motor, cognitive, and behavioral symptoms in fluctuating Parkinson\u2019s disease patients: A prospective longitudinal study","volume":"43","author":"Satolli","year":"2022","journal-title":"Neurol. Sci."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s10072-018-3628-3","article-title":"Efficacy of safinamide on non-motor symptoms in a cohort of patients affected by idiopathic Parkinson\u2019s disease","volume":"40","author":"Bianchi","year":"2019","journal-title":"Neurol. Sci."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1007\/s00702-023-02654-1","article-title":"Fatigue in fluctuating Parkinson\u2019s disease patients: Possible impact of safinamide","volume":"130","author":"Pauletti","year":"2023","journal-title":"J. Neural. Transm."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1007\/s00702-022-02538-w","article-title":"Non-motor symptoms burden in motor-fluctuating patients with Parkinson\u2019s disease may be alleviated by safinamide: The VALE-SAFI study","volume":"129","author":"Liguori","year":"2022","journal-title":"J. Neural. Transm."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"e01880","DOI":"10.1002\/brb3.1880","article-title":"Selegiline reduces daytime sleepiness in patients with Parkinson\u2019s disease","volume":"11","author":"Gallazzi","year":"2021","journal-title":"Brain Behav."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.pbb.2018.01.001","article-title":"Partial reversal of the effort-related motivational effects of tetrabenazine with the MAO-B inhibitor deprenyl (selegiline): Implications for treating motivational dysfunctions","volume":"166","author":"Rowland","year":"2018","journal-title":"Pharmacol. Biochem. Behav."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Parkinson Study Group (2005). A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: The PRESTO study. Arch. Neurol., 62, 241\u2013248.","DOI":"10.1001\/archneur.62.2.241"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/j.parkreldis.2013.06.001","article-title":"Rasagiline adjunct therapy in patients with Parkinson\u2019s disease: Post hoc analyses of the PRESTO and LARGO tri-als","volume":"19","author":"Elmer","year":"2013","journal-title":"Park. Relat. Disord."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Parkinson Study Group (2002). A controlled trial of rasagiline in early Parkinson disease: The TEMPO Study. Arch. Neurol., 59, 1937\u20131943.","DOI":"10.1001\/archneur.59.12.1937"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/j.parkreldis.2014.02.024","article-title":"Symptomatic efficacy of rasagiline monotherapy in early Parkinson\u2019s disease: Post-hoc analyses from the ADAGIO trial","volume":"20","author":"Jankovic","year":"2014","journal-title":"Park. Relat. Disord."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/S1474-4422(11)70073-4","article-title":"A double-blind, delayed-start trial of rasagiline in Parkinson\u2019s disease (the ADAGIO study): Prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes","volume":"10","author":"Rascol","year":"2011","journal-title":"Lancet Neurol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1111\/ene.13567","article-title":"Rasagiline improves polysomnographic sleep parameters in patients with Parkinson\u2019s disease: A double-blind, baseline-controlled trial","volume":"25","author":"Schrempf","year":"2018","journal-title":"Eur. J. Neurol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"141","DOI":"10.2147\/PROM.S196042","article-title":"Validation study of the Parkinson\u2019s Fatigue Scale in advanced Parkinson\u2019s disease","volume":"10","author":"Wetmore","year":"2019","journal-title":"Patient Relat. Outcome Meas."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"861","DOI":"10.2174\/1570159X16666180830100754","article-title":"Different Generations of Type-B Monoamine Oxidase Inhibitors in Parkinson\u2019s Disease: From Bench to Bedside","volume":"17","author":"Alborghetti","year":"2019","journal-title":"Curr. Neuropharmacol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/S0022-3565(24)38068-1","article-title":"Biochemical and electrophysiological studies on the mechanism of action of PNU-151774E, a novel antiepileptic compound","volume":"288","author":"Salvati","year":"1999","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1124\/jpet.117.245100","article-title":"Safinamide Differentially Modulates In Vivo Glutamate and GABA Release in the Rat Hippocampus and Basal Ganglia","volume":"364","author":"Morari","year":"2018","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1136\/jnnp.2008.159772","article-title":"Towards an understanding of fatigue in Parkinson disease","volume":"80","author":"Hagell","year":"2009","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.parkreldis.2018.06.033","article-title":"Safinamide effect on sleep disturbances and daytime sleepiness in motor fluctuating Parkinson\u2019s disease patients: A validated questionnaires-controlled study","volume":"57","author":"Liguori","year":"2018","journal-title":"Park. Relat. Disord."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1002\/mds.27461","article-title":"Fatigue in Parkinson\u2019s disease: A systematic review and meta-analysis","volume":"33","author":"Siciliano","year":"2018","journal-title":"Mov. Disord."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/8\/2598\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:12:04Z","timestamp":1760029924000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/8\/2598"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,10]]},"references-count":60,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,4]]}},"alternative-id":["jcm14082598"],"URL":"https:\/\/doi.org\/10.3390\/jcm14082598","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,10]]}}}